NCT07176702View on ClinicalTrials.gov

A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 5, 2027

Study Completion Date

September 1, 2027

Conditions
Metastatic PDACHER2-positive Status
Interventions
DRUG

HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy

"Drugs: HLX22 (15 mg/kg IV) + trastuzumab (8 mg/kg loading dose → 6 mg/kg maintenance) + nab-paclitaxel (125 mg/m² IV) + gemcitabine (1000 mg/m² IV).~Administration: Administered every 3 weeks until disease progression, unacceptable toxicity, or withdrawal."

All Listed Sponsors
lead

Liang Liu

OTHER